FDA Approves Vitrakvi (larotrectinib) for TRK Fusion Cancers

November 26, 2018 -- The U.S. Food and Drug Administration today granted accelerated approval to Vitrakvi (larotrectinib), a treatment for adult and pediatric patients whose cancers have a specific genetic feature (biomarker). This is the second...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news